Previous rAAV-mediated G6PC1 gene augmentation studies have shown efficacy in preclinical models of GSD-Ia9–12 and have been translated into an ongoing phase III clinical trial (NCT05139316). Here, G6PC1 is linked to disorder of glycogen metabolism.